MarketStudyReport.com adds “Global Carbidopa (CAS 28860-95-9) Market Outlook 2016-2021” new report to its research database. The report spread across 108 pages with table and figures in it.
Carbidopa (Lodosyn) is a drug given to people with Parkinson’s disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of peripheral levodopa to cross the blood?brain barrier for central nervous system effect.
Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as (-)-L-?-hydrazino-?-methyl-?-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its empirical formula is C10H14N2O4?H2O. Used in tandem with L-DOPA (also known as levodopa, a dopamine precursor converted in the body to dopamine), it increases the plasma half-life of levodopa from 50 minutes to 1? hours. CarbiDOPA cannot cross the blood?brain barrier, so it inhibits only peripheral DDC. It thus prevents the conversion of L-DOPA to dopamine peripherally. This reduces the side effects caused by dopamine on the periphery, as well as increasing the concentration of L-DOPA and dopamine in the brain.
Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-carbidopa-cas-28860-95-9-market-outlook-2016-2021/
This report provides detailed analysis of worldwide markets for Carbidopa (CAS 28860-95-9) from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors. It covers the key technological and market trends in the Carbidopa (CAS 28860-95-9) market and further lays out an analysis of the factors influencing the supply/demand for Carbidopa (CAS 28860-95-9), and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.
Global Carbidopa (CAS 28860-95-9) Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Carbidopa (CAS 28860-95-9) market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Carbidopa (CAS 28860-95-9) market are Novartis, Merck Sharp & Dohme, AbbVie, Allergan, Teva, Impax, WOCKHARDT, Wild Wind Pharmaceutical, Chiral Chem, Mylan N.V., Valeant, among others.
The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Carbidopa (CAS 28860-95-9) industry has been provided.
To receive personalized assistance, write to us @ firstname.lastname@example.org with the report title in the subject line along with your questions or call us at +1 866-764-2150